JPMorgan Chase & Co. cut its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 57.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 59,100 shares of the biotechnology company’s stock after selling 79,638 shares during the period. JPMorgan Chase & Co. owned 0.29% of AnaptysBio worth $1,414,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp bought a new stake in shares of AnaptysBio during the first quarter valued at approximately $373,000. TIAA CREF Investment Management LLC purchased a new position in shares of AnaptysBio in the first quarter worth $227,000. Geode Capital Management LLC purchased a new position in shares of AnaptysBio in the first quarter worth $1,522,000. Bank of America Corp DE purchased a new stake in AnaptysBio during the first quarter valued at $123,000. Finally, Endurant Capital Management LP purchased a new stake in AnaptysBio during the first quarter valued at $258,000. 59.16% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts recently commented on the company. Royal Bank Of Canada upped their price objective on AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Credit Suisse Group upped their price target on AnaptysBio from $38.00 to $85.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 10th. Robert W. Baird set a $69.00 price objective on AnaptysBio and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Zacks Investment Research lowered AnaptysBio from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $76.00 price target (up from $35.00) on shares of AnaptysBio in a research note on Friday, October 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. AnaptysBio has an average rating of “Buy” and a consensus price target of $71.71.
ILLEGAL ACTIVITY NOTICE: “JPMorgan Chase & Co. Sells 79,638 Shares of AnaptysBio, Inc. (ANAB)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/27/anaptysbio-inc-anab-position-trimmed-by-jpmorgan-chase-co.html.
In related news, major shareholder Holdings A/S Novo sold 70,706 shares of AnaptysBio stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the transaction, the insider now owns 3,009,949 shares in the company, valued at approximately $70,161,911.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 1,096,900 shares of company stock worth $23,321,392 in the last 90 days.
Shares of AnaptysBio, Inc. (ANAB) opened at 67.81 on Friday. The stock has a 50 day moving average price of $44.91 and a 200 day moving average price of $30.01. AnaptysBio, Inc. has a one year low of $15.17 and a one year high of $74.00. The stock’s market capitalization is $1.38 billion.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $3.45 million. Equities analysts forecast that AnaptysBio, Inc. will post ($1.99) earnings per share for the current year.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.